Company: GIFLF
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001104659-25-071915
Chunk: 1

Company: Grifols SA
Filing Date: 2025-07-30
Form: 6-K
Chunk 1
---
 at EUR 1.4 billion4 |

| · | On track to launch Fibrinogen in Europe                                                         
 in the fourth quarter of 2025 and in the first half of 2026 in the U.S., following FDA approval |

| · | Reinstated a dividend payment of EUR                                       
 0.15 per share, reflecting the company’s commitment to shareholder returns |

| · | Reaffirmed guidance for 20255,                                
 with improved guidance for FCF pre-M&A to EUR 375-425 million |

Barcelona, Spain – July 29, 2025– Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leader in plasma-derived medicines, today announced
results for the first half of 2025, driven by a second quarter marked by continued improvements across key operational and financial
metrics. These results reflect the ongoing execution of Grifols’ Value Creation Plan.

Revenues for the first half of the year grew
by 7.0% cc to EUR 3,677 million, driven by the performance of the Biopharma business, which increased by 8.2% cc. Adjusted EBITDA reached
EUR 876 million, up by 12.7% cc year-over-year, representing a 23.8% margin, supported by product mix, continuous improvement initiatives
and operational leverage. Net profit surged to EUR 177 million, reflecting a 387.6% increase compared to the same period of 2024.

Free cash flow pre-M&A significantly improved
to positive EUR 30 million in the second quarter, resulting in minus EUR 14 million for the first half of the year. This represents a
EUR 182 million year-over-year improvement, mainly driven by EBITDA growth, working capital management and reduced interest costs.

Grifols further strengthened its financial position,
reducing its leverage ratio to 4.2x, down from 4.5x in the previous quarter and 5.5x in the first half of 2024, with a liquidity position
of EUR 1.4 billion. The company remains focused on continuing to improve its credit profile.

| 1 | Operating or constant                                                  
 currency (cc) excludes changes rate variations reported in the period. |

| 2 | Free Cash Flow includes                                                                         
 cash from operating activities + cash flow from investing activities, both as per International 
 Financial Reporting Standards (IF